COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and
mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence …

Epithelial-mesenchymal transition (EMT) is able to drive metastasis during progression of
multiple cancer types, including non-small cell lung cancer (NSCLC). As resistance to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been proven
to be highly effective at preventing severe disease and mortality in healthy individuals; …

Background Tissue tumor mutational burden (TMB) has emerged as a potential biomarker
predicting response to anti‐programmed cell death‐1 protein receptor (PD‐1)/programmed …

Purpose To examine clinical predictors of tumor mutational burden (TMB), to explore the
association between TMB and DNA repair mutations, and to analyze TMB as a biomarker for …

Despite the efficacy of COVID-19 vaccines in healthy individuals, multiple myeloma (MM)
patients are immunocompromised and mount suboptimal humoral and cellular responses after …

Deficiencies in DNA repair pathways, including mismatch repair (MMR), have been linked
to higher tumor mutation burden and improved response to immune checkpoint inhibitors. …

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific
antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/…

Immunotherapy is emerging as a promising option for lung cancer treatment. Various
endothelial adhesion molecules, such as integrin and selectin, as well as various cellular barrier …

Background Accessible biomarkers are needed for immunotherapy in advanced non-small-cell
lung cancer (NSCLC). We previously described a multivariate risk prediction model, the …